A woman with BRCA1 mutation undergoes risk-reducing bilateral salpingo-oophorectomy (RRSO). Which additional statement about her breast cancer risk management is most evidence-based?
- A RRSO has no effect on breast cancer risk; only bilateral mastectomy reduces it
- B RRSO before age 40 reduces breast cancer risk in BRCA1 carriers by approximately 50% ✓
- C Tamoxifen chemoprevention is equally effective as RRSO for BRCA1 mutation carriers
- D RRSO after menopause has the same effect on breast cancer risk as RRSO before menopause
Correct answer: B. RRSO before age 40 reduces breast cancer risk in BRCA1 carriers by approximately 50%
Explanation
RRSO before age 40 in BRCA1 carriers reduces breast cancer risk by approximately 50-60%, primarily by removing the ovarian estrogen source that may drive HR-positive breast cancer. This benefit is more pronounced in BRCA2 carriers (who have more HR-positive tumors) but is also seen in BRCA1 carriers. RRSO after menopause confers minimal additional breast cancer risk reduction. Risk-reducing bilateral mastectomy offers ~90-95% risk reduction, but RRSO also reduces ovarian/fallopian tube cancer risk.
Reference: Bailey & Love's Short Practice of Surgery, 27th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.